120 related articles for article (PubMed ID: 36049549)
21. Role of serine 365 in BRAF V600E sensitivity to RAF inhibition.
Vido MJ; Rock J; Aplin AE
Pigment Cell Melanoma Res; 2021 Jul; 34(4):696-702. PubMed ID: 33000894
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
23. [Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].
Zhang H; Gao J; Guo W; Yu B; Yang H; Liu Y
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):86-91. PubMed ID: 35224961
[TBL] [Abstract][Full Text] [Related]
24. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O; Milia J; Cabarrou B; Bluthgen MV; Besse B; Smit EF; Wolf J; Peters S; Früh M; Koeberle D; Oulkhouir Y; Schuler M; Curioni-Fontecedro A; Huret B; Kerjouan M; Michels S; Pall G; Rothschild S; Schmid-Bindert G; Scheffler M; Veillon R; Wannesson L; Diebold J; Zalcman G; Filleron T; Mazières J
J Thorac Oncol; 2015 Oct; 10(10):1451-7. PubMed ID: 26200454
[TBL] [Abstract][Full Text] [Related]
25. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
26. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.
Zheng G; Tseng LH; Chen G; Haley L; Illei P; Gocke CD; Eshleman JR; Lin MT
BMC Cancer; 2015 Oct; 15():779. PubMed ID: 26498038
[TBL] [Abstract][Full Text] [Related]
27. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
28. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
29. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
30. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J
Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
[TBL] [Abstract][Full Text] [Related]
32. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M; Cascetta P; Planchard D
Lung Cancer; 2022 Jul; 169():102-114. PubMed ID: 35696864
[TBL] [Abstract][Full Text] [Related]
33. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
36. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
37. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
[TBL] [Abstract][Full Text] [Related]
38. Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V
Metzenmacher M; Goetz M; Herold T; Stuschke M; Aigner C; Darwiche K; Eberhardt WE; Schuler M; Wiesweg M
Clin Lung Cancer; 2021 Sep; 22(5):e668-e672. PubMed ID: 33551244
[No Abstract] [Full Text] [Related]
39. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
[TBL] [Abstract][Full Text] [Related]
40. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
